Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 13/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6697295 | 0.93 | OGA (0.49) | OGATP53GAASMN1; SMN2HTT | |
| SCHEMBL1343417 | 0.93 | SMN1; SMN2 (0.53) | OGATP53GAACHEK1SMN1; SMN2 | |
| SCHEMBL6697150 | 0.92 | OGA (0.47) | OGATP53GAASMN1; SMN2HTT | |
| SCHEMBL1343431 | 0.92 | OGA (0.48) | OGATP53GAACHEK1SMN1; SMN2 | |
| SCHEMBL6695257 | 0.91 | OGA (0.47) | OGATP53GAASMN1; SMN2HTT | |
| SCHEMBL6696934 | 0.91 | OGA (0.46) | OGATP53GAASMN1; SMN2HTT | |
| SCHEMBL2650893 | 0.86 | OGA (0.43) | OGATP53GAASMN1; SMN2HTT | |
| SCHEMBL1343075 | 0.84 | TP53 (0.53) | TP53GAASMN1; SMN2HTTPOLB | |
| SCHEMBL6696280 | 0.83 | TP53 (0.49) | TP53GAASMN1; SMN2HTT | |
| SCHEMBL6701130 | 0.83 | TP53 (0.49) | TP53GAASMN1; SMN2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | OGA 109/4885TP53 2961/4885GAA 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.